Cellectar Biosciences, Inc.
CLRBW
CLRBW was delisted on the 20th of August, 2019.
4 hedge funds and large institutions have $95K invested in Cellectar Biosciences, Inc. in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
53% less capital invested
Capital invested by funds: $201K → $95K (-$106K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$6.06K |
CLRBW Hedge Fund Activity: Q4 2016 in Review
4 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences, Inc. (CLRBW) for Q4 2016, worth a combined $95K — down 53% from $201K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CLRBW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $9. The largest seller was Sabby Management, cutting an estimated $6.06K.
- 4 institutional investors held Cellectar Biosciences, Inc. (CLRBW) as of Q4 2016, up from 3 in Q3 2016.
- Funds reported $95K of Cellectar Biosciences, Inc. stock for Q4 2016, down 53% quarter-over-quarter.
- 1 fund opened new Cellectar Biosciences, Inc. positions in Q4 2016 and 0 closed out, a net change of +1 holder.
- The largest Cellectar Biosciences, Inc. buyer in Q4 2016 was UBS Group, an estimated $9 added.
- The largest Cellectar Biosciences, Inc. seller in Q4 2016 was Sabby Management, an estimated $6.06K sold.
Based on aggregated 13F filings for Q4 2016.